Vimarsana
Biggest News Aggregation in the World

Page 17 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 - Vimarsana News

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration. REGEN-COV reduced the overall risk of progressing to symptom...

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT - Vimarsana News

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT - NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020 News provided by Share this article Share this article NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-s...

Biohaven Pharmaceutical : Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT - Vimarsana News

Biohaven Pharmaceutical : Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

Message : Required fields NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.  Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of...

Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members - Vimarsana News

Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members

Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members - Fallen service members names added to car hoods for respective branches of military served - - Funds raised support 22 Until None, a non-profit dedicated to ending veteran suicide - News provided by Share this article Share this article MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlot...

Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer - Vimarsana News

Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer

Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer News provided by Share this article Share this article WOODCLIFF LAKE, N.J., March 10, 2021 /PRNewswire/ -- Eisai ...